Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 5.21% |
| CYNOSURE INC | CYNO | 4.42% |
| DAWSON GEOPH | DWSN | 4.33% |
| MARRIOTT VAC | VAC | 3.27% |
| BLOOMIN' | BLMN | 2.93% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Hewlett-Packard Company (HPQ - Analyst Report) recently announced that it has resolved a patent infringement lawsuit pertaining to ink cartridges with Rio Branco Ltda. HP had sued Rio Branco in April last year.
Rio Branco Ltda., is a Brazilian distributor of Maxprint brand cartridges that are compatible with H-P printers. H-P had sued the Brazilian distributor over importing and selling the HP-compatible cartridges in Brazil.
Following the settlement, H-P's patents remained valid, and Rio Branco will no more be selling Maxprint cartridges. Maxprint will have to sell its inventory by December 1. Maxprint is also going to pay some of the litigation costs incurred by H-P.
However, H-P is exploring other channels to strengthen its presence in the Brazilian market. Some companies such as Canal Verde, Edeltec, Suprijet have confirmed that H-P's patents are valid and they have agreed to stop selling products that infringe upon H-P’s patents.
However, HP’s printing business continues to see many challenges, stemming mainly from macroeconomic concerns and secular changes in the printing market. While Lexmark’s (LXK) exit from the printing business could improve chances of share gains, this is not likely to be meaningful in the long term, as the inkjet market continues to shrink due to the easy availability of mobile media devices such as tablets and smartphones, which are reducing the need for taking printouts. Margins in the services business are also likely to remain weak this year.
The company is in dire need of rebounding, as it is constantly losing profit and market share. HP is implementing various strategies to generate growth. As discussed, the company is implementing some major restructuring actions to manage costs, drive growth and improve the health of its balance sheet.
Currently, the company retains a Zacks #3 Rank (Hold).
Read the full Analyst Report on HPQ